Perphenazine-Amitriptyline in Neurotic Depressed Outpatients: A Controlled Collaborative Study
ROBERT V. DESILVERIO M.D.1,
KARL RICKELS M.D.2,
CHARLES C. WEISE M.D.3,
EDWARD L. CLARK M.D.3, , and
JAMES HUTCHINSON M.D.3
1 Assistant director of psychopharmacology, Philadelphia General Hospital
2 Professor of psychiatry, University of Pennsylvania, 203 Piersol Bldg., 3400 Spruce St., Philadelphia, Pa. 19104, and director of psychopharmacology, Philadelphia General Hospital
3 Private practice and is member of the private practice research group, University of Pennsylvania
The combination of perphenazine-amitriptyline was compared to each of its constituents in a double-blind study conducted with 138 depressed and anxious-depressed neurotic outpatients. Irrespective of drug, general practice patients improved the most, clinic patients somewhat less, and private psychiatric patients the least. Drug differences were limited to a few significant and borderline-significant effects present only at two weeks; they indicated that perphenazine produced the greatest improvement at this period.
